Hutchison Chi-Med Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (33)

Latest Posts

About This Stock More About This Stock
Week In Review: BeiGene's BTK Inhibitor Approved In US And China Approval For PD-1 Expected In Two Months
Article By: ChinaBio® Today
Saturday, November 16, 2019 4:09 PM EST
Beijing's BeiGene had an outstanding week: its BTK drug, Brukinsa™, was approved for US use to treat mantle cell lymphoma, and its PD-1 candidate is poised for China approval before the end of the year to treat classical Hodgkin’s lymphoma.
In this article: HCM, BGNE, ASLN
Read
Week In Review: Chi-Med Plans $500 Million Hong Kong IPO
Article By: ChinaBio® Today
Saturday, April 20, 2019 4:48 PM EST
Hutchison China MediTech filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion. The IPO is expected to raise between $300 million and $500 million.
In this article: RNN, CASI, HCM
Read
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By: ChinaBio® Today
Saturday, December 1, 2018 4:44 PM EST
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
In this article: LLY, HCM, BGNE, MGNX, ZLAB, TCON, ZYME, BHVN
Read
Week In Review: Innovent's Hong Kong IPO: Raising $422 Million At $2 Billion Valuation
Article By: ChinaBio® Today
Saturday, October 20, 2018 4:16 PM EST
Innovent Biologics of Suzhou plans to raise $422 million in its Hong Kong IPO at a $2 billion valuation, according to multiple media reports. The company, formed in 2011, struck a major $1 billion collaboration with Lilly in 2015.
In this article: LLY, APDN, CGIX, HCM
Read
Week In Review: Jiangsu Hansoh To Raise Up To $3 Billion In Hong Kong IPO
Article By: ChinaBio® Today
Saturday, September 8, 2018 4:22 PM EST
Hansoh, a China pharma based in Lianyungang, Jiangsu province, has applied to stage an IPO on the Hong Kong exchange. Unlike most companies seeking Hong Kong IPOs, Hansoh is both profitable and established.
In this article: GSK, LLY, BGNE, ZLAB, ROG, HCM, MRK
Read

PARTNER HEADLINES

Latest Tweets for $HCM

No tweets yet!